Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 2/20 | 0.46 |
| ▸ | PPARA | Q07869 | 1/20 | 0.46 |
| ▸ | DRD4 | P21917 | 2/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.45 |
| ▸ | DRD3 | P35462 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1820819 | 0.85 | PPARA (0.45) | PPARGPPARAKDM4EPOLBALDH1A1 | |
| SCHEMBL1820377 | 0.83 | PPARG (0.44) | PPARGPPARAKDM4EPOLBALDH1A1 | |
| SCHEMBL5691818 | 0.82 | PPARG (0.61) | PPARGPPARAKDM4EPOLBALDH1A1 | |
| SCHEMBL1819564 | 0.79 | PPARG (0.43) | PPARGPPARAKDM4EPOLBALDH1A1 | |
| SCHEMBL27757832 | 0.79 | MAPT (0.55) | PPARGPPARAKDM4EPOLBALDH1A1 | |
| SCHEMBL27520136 | 0.77 | PPARG (0.47) | PPARGPPARAKDM4EPOLBALDH1A1 | |
| SCHEMBL1819039 | 0.76 | PPARA (0.46) | PPARGPPARAKDM4EPOLBALDH1A1 | |
| SCHEMBL1818640 | 0.76 | HDAC3 (0.58) | PPARGPPARAPOLBRAB9AKCNN4 | |
| SCHEMBL1821867 | 0.75 | PPARA (0.45) | PPARGPPARAKDM4EPOLBALDH1A1 | |
| SCHEMBL1823516 | 0.75 | PPARA (0.45) | PPARGPPARAKDM4EPOLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8710053-B2 | Plant disease control composition and its use | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2014-04-29 | — | — | US | disclosed |
| US-20130065891-A1 | PLANT DISEASE CONTROL COMPOSITION AND ITS USE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2013-03-14 | — | — | US | disclosed |
| US-7947712-B2 | Antiarthritic agents; asthma; chronic obstructive pulminary diosrders; atherosclerosis; vision defects; hepatitis; central nervous system disorders; cardiovascular disorders; wound healing agents; restenosis; cirrhosis; multiple sclerosis; glomerulonephritis; graft versus host disease; antidiabetic agent | WYETH LLC (US) | 2011-05-24 | — | — | US | disclosed |
| US-20080269213-A1 | 8-Hydroxyquinoline compounds and methods thereof | WYETH (US) | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269213-A1 | 8-Hydroxyquinoline compounds and methods thereof | MMP8, MMP26, MMP9 | PPARG 1416/4885PPARA 2595/4885DRD4 2190/4885 |
| US-20130065891-A1 | PLANT DISEASE CONTROL COMPOSITION AND ITS USE | NQO2, RDX, CNPY2 | PPARG 2817/4885PPARA 3511/4885DRD4 3560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.